chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pharyngeal hypoaesthesia, Pyrexia, Throat tightness, Urticaria, Ventricular extrasystoles
Clinical narrative: Full blown allergic reaction to vaccine within minutes of administration/redness all over her body, lip swelling, severe allergic reaction; redness all over her body, lip swelling, severe allergic reaction; redness all over her body, lip swelling, severe allergic reaction; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number and expiry date were not reported), via an unspecified route of administration on 11Mar2021 (at the age of 47 years old) at a single dose for COVID-19 immunization. Vaccination was done in a Public Health Clinic/Veterans Administration facility. Medical history included connective tissue disorder, high cholesterol, and chronic hip/labrum issues, all from an unknown date and unknown if ongoing. Patient was not pregnant. There was no COVID prior vaccination and not COVID tested post vaccination. The patient's concomitant medications were not reported. The patient previously received flu vaccine for immunization and experienced known allergies: flu vaccine. The patient experienced full blown allergic reaction to vaccine within minutes of administration/redness all over her body, lip swelling, severe allergic reaction on 11Mar2021. It was reported that the patient was taken to the ER by EMS for observation, treated and released, all on 11Mar2021. She took Benadryl at the vaccination site and was given prednisone treatment at the hospital. The outcome of the event was recovering.  Information on the batch/lot number has been requested.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Erythema, Hypersensitivity, Lip swelling
Clinical narrative: Full blown allergic reaction to vaccine within minutes of administration/redness all over her body, lip swelling, severe allergic reaction; redness all over her body, lip swelling, severe allergic reaction; redness all over her body, lip swelling, severe allergic reaction; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number and expiry date were not reported), via an unspecified route of administration on 11Mar2021 (at the age of 47 years old) at a single dose for COVID-19 immunization. Vaccination was done in a Public Health Clinic/Veterans Administration facility. Medical history included connective tissue disorder, high cholesterol, and chronic hip/labrum issues, all from an unknown date and unknown if ongoing. Patient was not pregnant. There was no COVID prior vaccination and not COVID tested post vaccination. The patient's concomitant medications were not reported. The patient previously received flu vaccine for immunization and experienced known allergies: flu vaccine. The patient experienced full blown allergic reaction to vaccine within minutes of administration/redness all over her body, lip swelling, severe allergic reaction on 11Mar2021. It was reported that the patient was taken to the ER by EMS for observation, treated and released, all on 11Mar2021. She took Benadryl at the vaccination site and was given prednisone treatment at the hospital. The outcome of the event was recovering.  Information on the batch/lot number has been requested.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Anaphylactic reaction, Hypertension, Pharyngeal swelling, Swollen tongue, Throat irritation
Clinical narrative: Anaphylaxis; This is a spontaneous report from a two contactable consumer (patient and office assistant). A 44-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EN6208), via an unspecified route of administration in left arm on 12Mar2021 at 18:30 as a single dose for COVID-19 immunization. Medical history included hypothyroidism, bipolar and high blood pressure. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. It was unknown if patient had covid prior vaccination. Concomitant medication included lamotrigine (LAMICTAL), levothyroxine (MANUFACTURER UNKNOWN), amlodipine (MANUFACTURER UNKNOWN) and glucosamine (MANUFACTURER UNKNOWN). On 12Mar2021 at 18:45, the patient experienced anaphylaxis. It was reported that patient visited emergency room/department or urgent care. The patient took Benadryl and 2 epinephrine shots as a treatment. It was reported that COVID test was not done after post vaccination. The outcome of the event was resolved on Mar2021.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tongue pruritus
Clinical narrative: Anaphylaxis; This is a spontaneous report from a two contactable consumer (patient and office assistant). A 44-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EN6208), via an unspecified route of administration in left arm on 12Mar2021 at 18:30 as a single dose for COVID-19 immunization. Medical history included hypothyroidism, bipolar and high blood pressure. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. It was unknown if patient had covid prior vaccination. Concomitant medication included lamotrigine (LAMICTAL), levothyroxine (MANUFACTURER UNKNOWN), amlodipine (MANUFACTURER UNKNOWN) and glucosamine (MANUFACTURER UNKNOWN). On 12Mar2021 at 18:45, the patient experienced anaphylaxis. It was reported that patient visited emergency room/department or urgent care. The patient took Benadryl and 2 epinephrine shots as a treatment. It was reported that COVID test was not done after post vaccination. The outcome of the event was resolved on Mar2021.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Anaphylactic reaction
Clinical narrative: Anaphylaxis; This is a spontaneous report from a two contactable consumer (patient and office assistant). A 44-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EN6208), via an unspecified route of administration in left arm on 12Mar2021 at 18:30 as a single dose for COVID-19 immunization. Medical history included hypothyroidism, bipolar and high blood pressure. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. It was unknown if patient had covid prior vaccination. Concomitant medication included lamotrigine (LAMICTAL), levothyroxine (MANUFACTURER UNKNOWN), amlodipine (MANUFACTURER UNKNOWN) and glucosamine (MANUFACTURER UNKNOWN). On 12Mar2021 at 18:45, the patient experienced anaphylaxis. It was reported that patient visited emergency room/department or urgent care. The patient took Benadryl and 2 epinephrine shots as a treatment. It was reported that COVID test was not done after post vaccination. The outcome of the event was resolved on Mar2021.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain, Abdominal pain upper, Arthralgia, Chest pain, Chills
Clinical narrative: it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); This was characterized by severe abdominal pain; headache; extreme dizziness; chest pain; brain fog; numbness in feet; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient (not pregnant) received bnt162b2, via an unspecified route of administration, in left arm on 03Mar2021 09:00 (second dose, Batch/Lot Number: EN6203), via an unspecified route of administration in left arm on 09Feb2021 12:45 (first dose, Lot number: EC(L?)8982) both as single dose for covid-19 immunization. Medical history included acute intermittent porphyria, migraine, hypertension (HTN), dermatitis contact (Known allergies: adhesives (contact dermatitis)), COVID-19 (If COVID prior vaccination: Yes) all from unknown date and unknown if ongoing. Concomitant medications included givosiran sodium (GIVLAARI); lisinopril; hemin (PANHEMATIN DRY); zolmitriptan taken for an unspecified indication, start and stop date were not reported. The patient experienced after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain), it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria), this was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet all on 03Mar2021 20:00. After each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain) and it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria). This was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet. She received treatment for the attack and symptoms resolved after several days. The treatment included: Intravenous treatment with hemin (PANHEMATIN). The events resulted in doctor or other healthcare professional office/clinic visit. The outcome of events was resolved. Facility type vaccine was hospital. No other vaccine in four weeks. No COVID tested post vaccination.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Dysstasia, Fatigue, Gait inability, Headache
Clinical narrative: it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); This was characterized by severe abdominal pain; headache; extreme dizziness; chest pain; brain fog; numbness in feet; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient (not pregnant) received bnt162b2, via an unspecified route of administration, in left arm on 03Mar2021 09:00 (second dose, Batch/Lot Number: EN6203), via an unspecified route of administration in left arm on 09Feb2021 12:45 (first dose, Lot number: EC(L?)8982) both as single dose for covid-19 immunization. Medical history included acute intermittent porphyria, migraine, hypertension (HTN), dermatitis contact (Known allergies: adhesives (contact dermatitis)), COVID-19 (If COVID prior vaccination: Yes) all from unknown date and unknown if ongoing. Concomitant medications included givosiran sodium (GIVLAARI); lisinopril; hemin (PANHEMATIN DRY); zolmitriptan taken for an unspecified indication, start and stop date were not reported. The patient experienced after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain), it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria), this was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet all on 03Mar2021 20:00. After each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain) and it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria). This was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet. She received treatment for the attack and symptoms resolved after several days. The treatment included: Intravenous treatment with hemin (PANHEMATIN). The events resulted in doctor or other healthcare professional office/clinic visit. The outcome of events was resolved. Facility type vaccine was hospital. No other vaccine in four weeks. No COVID tested post vaccination.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia, Metabolic function test, Migraine, Nausea, Pyrexia
Clinical narrative: it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); This was characterized by severe abdominal pain; headache; extreme dizziness; chest pain; brain fog; numbness in feet; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient (not pregnant) received bnt162b2, via an unspecified route of administration, in left arm on 03Mar2021 09:00 (second dose, Batch/Lot Number: EN6203), via an unspecified route of administration in left arm on 09Feb2021 12:45 (first dose, Lot number: EC(L?)8982) both as single dose for covid-19 immunization. Medical history included acute intermittent porphyria, migraine, hypertension (HTN), dermatitis contact (Known allergies: adhesives (contact dermatitis)), COVID-19 (If COVID prior vaccination: Yes) all from unknown date and unknown if ongoing. Concomitant medications included givosiran sodium (GIVLAARI); lisinopril; hemin (PANHEMATIN DRY); zolmitriptan taken for an unspecified indication, start and stop date were not reported. The patient experienced after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain), it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria), this was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet all on 03Mar2021 20:00. After each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain) and it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria). This was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet. She received treatment for the attack and symptoms resolved after several days. The treatment included: Intravenous treatment with hemin (PANHEMATIN). The events resulted in doctor or other healthcare professional office/clinic visit. The outcome of events was resolved. Facility type vaccine was hospital. No other vaccine in four weeks. No COVID tested post vaccination.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Urine analysis
Clinical narrative: it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); This was characterized by severe abdominal pain; headache; extreme dizziness; chest pain; brain fog; numbness in feet; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient (not pregnant) received bnt162b2, via an unspecified route of administration, in left arm on 03Mar2021 09:00 (second dose, Batch/Lot Number: EN6203), via an unspecified route of administration in left arm on 09Feb2021 12:45 (first dose, Lot number: EC(L?)8982) both as single dose for covid-19 immunization. Medical history included acute intermittent porphyria, migraine, hypertension (HTN), dermatitis contact (Known allergies: adhesives (contact dermatitis)), COVID-19 (If COVID prior vaccination: Yes) all from unknown date and unknown if ongoing. Concomitant medications included givosiran sodium (GIVLAARI); lisinopril; hemin (PANHEMATIN DRY); zolmitriptan taken for an unspecified indication, start and stop date were not reported. The patient experienced after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain), it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria), this was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet all on 03Mar2021 20:00. After each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain) and it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria). This was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet. She received treatment for the attack and symptoms resolved after several days. The treatment included: Intravenous treatment with hemin (PANHEMATIN). The events resulted in doctor or other healthcare professional office/clinic visit. The outcome of events was resolved. Facility type vaccine was hospital. No other vaccine in four weeks. No COVID tested post vaccination.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain, Chest pain, Chills, Condition aggravated, Dizziness
Clinical narrative: it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); This was characterized by severe abdominal pain; headache; extreme dizziness; chest pain; brain fog; numbness in feet; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient (not pregnant) received bnt162b2, via an unspecified route of administration, in left arm on 03Mar2021 09:00 (second dose, Batch/Lot Number: EN6203), via an unspecified route of administration in left arm on 09Feb2021 12:45 (first dose, Lot number: EC(L?)8982) both as single dose for covid-19 immunization. Medical history included acute intermittent porphyria, migraine, hypertension (HTN), dermatitis contact (Known allergies: adhesives (contact dermatitis)), COVID-19 (If COVID prior vaccination: Yes) all from unknown date and unknown if ongoing. Concomitant medications included givosiran sodium (GIVLAARI); lisinopril; hemin (PANHEMATIN DRY); zolmitriptan taken for an unspecified indication, start and stop date were not reported. The patient experienced after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain), it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria), this was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet all on 03Mar2021 20:00. After each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain) and it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria). This was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet. She received treatment for the attack and symptoms resolved after several days. The treatment included: Intravenous treatment with hemin (PANHEMATIN). The events resulted in doctor or other healthcare professional office/clinic visit. The outcome of events was resolved. Facility type vaccine was hospital. No other vaccine in four weeks. No COVID tested post vaccination.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Feeling abnormal, Headache, Hypoaesthesia, Myalgia, Porphyria acute
Clinical narrative: it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); This was characterized by severe abdominal pain; headache; extreme dizziness; chest pain; brain fog; numbness in feet; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient (not pregnant) received bnt162b2, via an unspecified route of administration, in left arm on 03Mar2021 09:00 (second dose, Batch/Lot Number: EN6203), via an unspecified route of administration in left arm on 09Feb2021 12:45 (first dose, Lot number: EC(L?)8982) both as single dose for covid-19 immunization. Medical history included acute intermittent porphyria, migraine, hypertension (HTN), dermatitis contact (Known allergies: adhesives (contact dermatitis)), COVID-19 (If COVID prior vaccination: Yes) all from unknown date and unknown if ongoing. Concomitant medications included givosiran sodium (GIVLAARI); lisinopril; hemin (PANHEMATIN DRY); zolmitriptan taken for an unspecified indication, start and stop date were not reported. The patient experienced after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain), it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria), this was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet all on 03Mar2021 20:00. After each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain) and it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria). This was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet. She received treatment for the attack and symptoms resolved after several days. The treatment included: Intravenous treatment with hemin (PANHEMATIN). The events resulted in doctor or other healthcare professional office/clinic visit. The outcome of events was resolved. Facility type vaccine was hospital. No other vaccine in four weeks. No COVID tested post vaccination.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia
Clinical narrative: it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); it triggered an exacerbation (attack) of my underlying genetic disease (acute intermittent porphyria); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain); This was characterized by severe abdominal pain; headache; extreme dizziness; chest pain; brain fog; numbness in feet; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient (not pregnant) received bnt162b2, via an unspecified route of administration, in left arm on 03Mar2021 09:00 (second dose, Batch/Lot Number: EN6203), via an unspecified route of administration in left arm on 09Feb2021 12:45 (first dose, Lot number: EC(L?)8982) both as single dose for covid-19 immunization. Medical history included acute intermittent porphyria, migraine, hypertension (HTN), dermatitis contact (Known allergies: adhesives (contact dermatitis)), COVID-19 (If COVID prior vaccination: Yes) all from unknown date and unknown if ongoing. Concomitant medications included givosiran sodium (GIVLAARI); lisinopril; hemin (PANHEMATIN DRY); zolmitriptan taken for an unspecified indication, start and stop date were not reported. The patient experienced after each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain), it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria), this was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet all on 03Mar2021 20:00. After each vaccination, 12 hours later typical side effects developed (low grade fever, chills, muscles pain) and it triggered an exacerbation (attack) of her underlying genetic disease (acute intermittent porphyria). This was characterized by severe abdominal pain, headache, extreme dizziness, chest pain, brain fog, numbness in feet. She received treatment for the attack and symptoms resolved after several days. The treatment included: Intravenous treatment with hemin (PANHEMATIN). The events resulted in doctor or other healthcare professional office/clinic visit. The outcome of events was resolved. Facility type vaccine was hospital. No other vaccine in four weeks. No COVID tested post vaccination.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Fatigue, Nausea, Palpitations
Clinical narrative: Heart palpitations; Extreme dizziness; Nausea; Fatigue; This is a spontaneous report from a contactable consumer (patient) from a Sponsored program. A 77-years-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9269), via an unspecified route of administration on 11Feb2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient was in good health and had a bad reaction to the first dose of the vaccine. On 12Feb2021, the patient experienced fatigue. On 18Feb2021, the patient ended up in the hospital emergency room with extreme dizziness, nausea, heart palpitations and fatigue. The second dose for the vaccine was scheduled for 04Mar2021. The outcome of events dizziness, nausea, heart palpitations, fatigue was unknown.
Age: 44.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dysphonia, Nasal congestion, Throat tightness
Clinical narrative: sore throat; nasal congestion; very difficult to breath; This is a spontaneous report from a contactable consumer (patient). A 44-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 14Mar2021 16:00 as SINGLE DOSE for covid-19 immunisation. There was no other vaccine in four weeks. No known allergies. The patient medical history was not reported.Concomitant medications included atorvastatin and Irbesartan, both taken for an unspecified indication, start and stop date were not reported. The patient started with sore throat that got progressively worse and nasal congestion. The 2 combined made it very difficult to breath. The events onset date were reported as 14Mar2021 05:15 PM, they resulted in Emergency room/department or urgent care. Patient received Benadryl, Pepcid and IV for treatment, and recovered in Mar2021. Patient didn't have Covid prior vaccination nor teasted Covid post vaccination.  Information about lot/batch number has been requested.
Age: 44.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Nasal congestion, Oropharyngeal pain
Clinical narrative: sore throat; nasal congestion; very difficult to breath; This is a spontaneous report from a contactable consumer (patient). A 44-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 14Mar2021 16:00 as SINGLE DOSE for covid-19 immunisation. There was no other vaccine in four weeks. No known allergies. The patient medical history was not reported.Concomitant medications included atorvastatin and Irbesartan, both taken for an unspecified indication, start and stop date were not reported. The patient started with sore throat that got progressively worse and nasal congestion. The 2 combined made it very difficult to breath. The events onset date were reported as 14Mar2021 05:15 PM, they resulted in Emergency room/department or urgent care. Patient received Benadryl, Pepcid and IV for treatment, and recovered in Mar2021. Patient didn't have Covid prior vaccination nor teasted Covid post vaccination.  Information about lot/batch number has been requested.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: she tested positive for COVID; she tested positive for COVID; This is a spontaneous report from a contactable consumer reporting for herself.   A 41-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL3302) on 13Jan2021 at 10:15 am (age at vaccination 40 years) at single dose on right arm via an unspecified route of administration  for COVID-19 immunization. First dose of BNT162B2 was administered on 23Dec2020 (lot number: EJ1685) on right arm at single dose. Relevant medical history and concomitant medications were not reported. On 13Mar2021 the patient tested positive for Covid-19.  At the time of the reporting events outcome was unknown
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Exposure to SARS-CoV-2, Feeling abnormal, Mobility decreased, Neck pain
Clinical narrative: she tested positive for COVID; she tested positive for COVID; This is a spontaneous report from a contactable consumer reporting for herself.   A 41-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL3302) on 13Jan2021 at 10:15 am (age at vaccination 40 years) at single dose on right arm via an unspecified route of administration  for COVID-19 immunization. First dose of BNT162B2 was administered on 23Dec2020 (lot number: EJ1685) on right arm at single dose. Relevant medical history and concomitant medications were not reported. On 13Mar2021 the patient tested positive for Covid-19.  At the time of the reporting events outcome was unknown
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Pain, Pain in extremity, Swelling, Ultrasound scan normal
Clinical narrative: she tested positive for COVID; she tested positive for COVID; This is a spontaneous report from a contactable consumer reporting for herself.   A 41-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL3302) on 13Jan2021 at 10:15 am (age at vaccination 40 years) at single dose on right arm via an unspecified route of administration  for COVID-19 immunization. First dose of BNT162B2 was administered on 23Dec2020 (lot number: EJ1685) on right arm at single dose. Relevant medical history and concomitant medications were not reported. On 13Mar2021 the patient tested positive for Covid-19.  At the time of the reporting events outcome was unknown
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: she tested positive for COVID; she tested positive for COVID; This is a spontaneous report from a contactable consumer reporting for herself.   A 41-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL3302) on 13Jan2021 at 10:15 am (age at vaccination 40 years) at single dose on right arm via an unspecified route of administration  for COVID-19 immunization. First dose of BNT162B2 was administered on 23Dec2020 (lot number: EJ1685) on right arm at single dose. Relevant medical history and concomitant medications were not reported. On 13Mar2021 the patient tested positive for Covid-19.  At the time of the reporting events outcome was unknown
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: she tested positive for COVID; she tested positive for COVID; This is a spontaneous report from a contactable consumer reporting for herself.   A 41-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL3302) on 13Jan2021 at 10:15 am (age at vaccination 40 years) at single dose on right arm via an unspecified route of administration  for COVID-19 immunization. First dose of BNT162B2 was administered on 23Dec2020 (lot number: EJ1685) on right arm at single dose. Relevant medical history and concomitant medications were not reported. On 13Mar2021 the patient tested positive for Covid-19.  At the time of the reporting events outcome was unknown
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: tested positive after getting her 2nd dose; tested positive after getting her 2nd dose; This is a spontaneous report from a Pfizer-sponsored program. A contactable female consumer reported that:  A contactable female consumer (patient) reported that she received the second dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number not provided), via an unspecified route of administration on 13Jan2021 at single dose for covid-19 immunisation. Medical history was unknown. Relevant concomitant medications were unknown. On an unspecified date after the second dose of vaccine the patient resulted positive to SARS-CoV-2 test.    Information on lot/batch number has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Exposure to SARS-CoV-2, Feeling abnormal, Mobility decreased, Neck pain
Clinical narrative: tested positive after getting her 2nd dose; tested positive after getting her 2nd dose; This is a spontaneous report from a Pfizer-sponsored program. A contactable female consumer reported that:  A contactable female consumer (patient) reported that she received the second dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number not provided), via an unspecified route of administration on 13Jan2021 at single dose for covid-19 immunisation. Medical history was unknown. Relevant concomitant medications were unknown. On an unspecified date after the second dose of vaccine the patient resulted positive to SARS-CoV-2 test.    Information on lot/batch number has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Pain, Pain in extremity, Swelling, Ultrasound scan normal
Clinical narrative: tested positive after getting her 2nd dose; tested positive after getting her 2nd dose; This is a spontaneous report from a Pfizer-sponsored program. A contactable female consumer reported that:  A contactable female consumer (patient) reported that she received the second dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number not provided), via an unspecified route of administration on 13Jan2021 at single dose for covid-19 immunisation. Medical history was unknown. Relevant concomitant medications were unknown. On an unspecified date after the second dose of vaccine the patient resulted positive to SARS-CoV-2 test.    Information on lot/batch number has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: tested positive after getting her 2nd dose; tested positive after getting her 2nd dose; This is a spontaneous report from a Pfizer-sponsored program. A contactable female consumer reported that:  A contactable female consumer (patient) reported that she received the second dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number not provided), via an unspecified route of administration on 13Jan2021 at single dose for covid-19 immunisation. Medical history was unknown. Relevant concomitant medications were unknown. On an unspecified date after the second dose of vaccine the patient resulted positive to SARS-CoV-2 test.    Information on lot/batch number has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: tested positive after getting her 2nd dose; tested positive after getting her 2nd dose; This is a spontaneous report from a Pfizer-sponsored program. A contactable female consumer reported that:  A contactable female consumer (patient) reported that she received the second dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number not provided), via an unspecified route of administration on 13Jan2021 at single dose for covid-19 immunisation. Medical history was unknown. Relevant concomitant medications were unknown. On an unspecified date after the second dose of vaccine the patient resulted positive to SARS-CoV-2 test.    Information on lot/batch number has been requested.
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood test, Cellulitis, Computerised tomogram abnormal, Gangrene, Incorrect route of product administration
Clinical narrative: shot was given to me high up almost on top of shoulder not in the muscle; Had to remove cellulitis that turned into gangrene; my right elbow area started to swell and turn red and get hot; my right elbow area started to swell and turn red and get hot; This is a spontaneous report from a contactable consumer (Patient). A 48-years-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection) via unspecified route of administration at right arm on 27Jan2021 at 11:00 (at the age of 48-years-old) as a single dose for covid-19 immunization. No other vaccine on same date. The patient medical history included lots of surgeries, covid-19 (covid prior vaccination). Concomitant medications included lorazepam (LORAZEPAM) and alprazolam (XANAX) (In two weeks). Patient had known allergies to narcotics. On 27Jan2021 at 11:00 the patient reported that my right elbow area started to swell and turn red and get hot. The shot was given to me high up almost on top of shoulder not in the muscle, and the Orthopedic Dr stated that yes it was due to shot placement. I ended up spending 4 days in the hospital and having surgery in elbow area. Had to remove cellulitis that turned into gangrene. Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Prolongation of existing hospitalization (vaccine received during existing hospitalization), Life threatening illness (immediate risk of death from the event)]. No covid tested post vaccination. The patient not received other vaccine in four weeks. Patient received treatment as emergency surgery. The outcome of events was recovered with sequelae.  Information about Batch/Lot number has been requested.
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Joint injection, Pain in extremity, Pyrexia, Surgery
Clinical narrative: shot was given to me high up almost on top of shoulder not in the muscle; Had to remove cellulitis that turned into gangrene; my right elbow area started to swell and turn red and get hot; my right elbow area started to swell and turn red and get hot; This is a spontaneous report from a contactable consumer (Patient). A 48-years-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection) via unspecified route of administration at right arm on 27Jan2021 at 11:00 (at the age of 48-years-old) as a single dose for covid-19 immunization. No other vaccine on same date. The patient medical history included lots of surgeries, covid-19 (covid prior vaccination). Concomitant medications included lorazepam (LORAZEPAM) and alprazolam (XANAX) (In two weeks). Patient had known allergies to narcotics. On 27Jan2021 at 11:00 the patient reported that my right elbow area started to swell and turn red and get hot. The shot was given to me high up almost on top of shoulder not in the muscle, and the Orthopedic Dr stated that yes it was due to shot placement. I ended up spending 4 days in the hospital and having surgery in elbow area. Had to remove cellulitis that turned into gangrene. Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Prolongation of existing hospitalization (vaccine received during existing hospitalization), Life threatening illness (immediate risk of death from the event)]. No covid tested post vaccination. The patient not received other vaccine in four weeks. Patient received treatment as emergency surgery. The outcome of events was recovered with sequelae.  Information about Batch/Lot number has been requested.
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Cellulitis gangrenous, Joint swelling, Product administered at inappropriate site, Vaccination site joint erythema
Clinical narrative: shot was given to me high up almost on top of shoulder not in the muscle; Had to remove cellulitis that turned into gangrene; my right elbow area started to swell and turn red and get hot; my right elbow area started to swell and turn red and get hot; This is a spontaneous report from a contactable consumer (Patient). A 48-years-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection) via unspecified route of administration at right arm on 27Jan2021 at 11:00 (at the age of 48-years-old) as a single dose for covid-19 immunization. No other vaccine on same date. The patient medical history included lots of surgeries, covid-19 (covid prior vaccination). Concomitant medications included lorazepam (LORAZEPAM) and alprazolam (XANAX) (In two weeks). Patient had known allergies to narcotics. On 27Jan2021 at 11:00 the patient reported that my right elbow area started to swell and turn red and get hot. The shot was given to me high up almost on top of shoulder not in the muscle, and the Orthopedic Dr stated that yes it was due to shot placement. I ended up spending 4 days in the hospital and having surgery in elbow area. Had to remove cellulitis that turned into gangrene. Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Prolongation of existing hospitalization (vaccine received during existing hospitalization), Life threatening illness (immediate risk of death from the event)]. No covid tested post vaccination. The patient not received other vaccine in four weeks. Patient received treatment as emergency surgery. The outcome of events was recovered with sequelae.  Information about Batch/Lot number has been requested.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Fatigue, Laboratory test normal, Magnetic resonance imaging head, Magnetic resonance imaging neck
Clinical narrative: I could barely move; a lot of weakness; fell at home twice; This is a spontaneous report from a contactable nurse (patient). A 50-year-old non-pregnant female patient received the first dose of bnt162b2 (Batch/Lot Number: EM9809), via an unspecified route of administration, administered in the right arm on 10Mar2021 12:15 as a single dose for covid-19 immunization. The patient's medical history included multiple sclerosis known allergies (not specified) from an unknown date and unknown if ongoing. On 11Mar2021, the day after the vaccine patient had a lot of weakness and fell at home twice. No injury from falls. They were more guided drops to ground. Patient was seen in the emergency room (ER). The next morning  12Mar2021, patient could barely move from weakness. She went back to ER and was admitted for high dose IV steroids.  Work up while in hospital lead the doctors to conclude it was from the vaccine. It was reported that the patient was hospitalized for 3 days. The patient was recovering from the events at the time of the report. The patient has not had Covid-19 prior to vaccination and  was not tested for Covid-10 post vaccination.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Mobility decreased
Clinical narrative: I could barely move; a lot of weakness; fell at home twice; This is a spontaneous report from a contactable nurse (patient). A 50-year-old non-pregnant female patient received the first dose of bnt162b2 (Batch/Lot Number: EM9809), via an unspecified route of administration, administered in the right arm on 10Mar2021 12:15 as a single dose for covid-19 immunization. The patient's medical history included multiple sclerosis known allergies (not specified) from an unknown date and unknown if ongoing. On 11Mar2021, the day after the vaccine patient had a lot of weakness and fell at home twice. No injury from falls. They were more guided drops to ground. Patient was seen in the emergency room (ER). The next morning  12Mar2021, patient could barely move from weakness. She went back to ER and was admitted for high dose IV steroids.  Work up while in hospital lead the doctors to conclude it was from the vaccine. It was reported that the patient was hospitalized for 3 days. The patient was recovering from the events at the time of the report. The patient has not had Covid-19 prior to vaccination and  was not tested for Covid-10 post vaccination.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Fall, Mobility decreased
Clinical narrative: I could barely move; a lot of weakness; fell at home twice; This is a spontaneous report from a contactable nurse (patient). A 50-year-old non-pregnant female patient received the first dose of bnt162b2 (Batch/Lot Number: EM9809), via an unspecified route of administration, administered in the right arm on 10Mar2021 12:15 as a single dose for covid-19 immunization. The patient's medical history included multiple sclerosis known allergies (not specified) from an unknown date and unknown if ongoing. On 11Mar2021, the day after the vaccine patient had a lot of weakness and fell at home twice. No injury from falls. They were more guided drops to ground. Patient was seen in the emergency room (ER). The next morning  12Mar2021, patient could barely move from weakness. She went back to ER and was admitted for high dose IV steroids.  Work up while in hospital lead the doctors to conclude it was from the vaccine. It was reported that the patient was hospitalized for 3 days. The patient was recovering from the events at the time of the report. The patient has not had Covid-19 prior to vaccination and  was not tested for Covid-10 post vaccination.
Age: 24.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arrhythmia, Electrocardiogram
Clinical narrative: Heart arrhythmia; This is a spontaneous report from a contactable consumer (patient herself). A 24-year-old female patient received the first dose of BNT162B2 (Pfizer-BIONTECH COVID-19 Vaccine), via an unspecified route of administration in the right arm on 08Mar2021 at 11:00 AM as a single dose for COVID-19 immunisation. The patient had no other vaccines in four weeks, did not have COVID prior to the vaccination, was not tested for COVID after the vaccination, had no known allergies, and no other medical history. There were no concomitant medications. The patient experienced heart arrhythmia on 09Mar202. Therapeutic measures were taken as a result of heart arrhythmia which included Beta blocker/s. Outcome of the event was unknown.  Information about the lot/batch number has been requested.